首页> 外文期刊>Inflammation Research >The potential application of nicotinic acetylcholine receptor agonists for the treatment of rheumatoid arthritis
【24h】

The potential application of nicotinic acetylcholine receptor agonists for the treatment of rheumatoid arthritis

机译:烟碱型乙酰胆碱受体激动剂在类风湿关节炎治疗中的潜在应用

获取原文
获取原文并翻译 | 示例
           

摘要

Although the disease-modifying anti-rheumatic drugs (DMARD) have been widely used in clinics, rheumatoid arthritis (RA) is not completely curable so far. Hence, to seek new drugs for the treatment of RA has become a pursuing goal of rheumatologists and orthopedic surgeons. Since the major pathological characteristic of RA is inflammation, the exploration of anti-inflammatory drugs has become a hotspot. Moreover, the anti-inflammatory and anti-nociceptive functions of nicotinic acetylcholine receptors as well as the related mechanisms have been recently discovered. Based on the abovementioned, it is promising that the nicotinic acetylcholine receptor agonists will be applied for the treatment of RA. Following in vitro, in vivo experiments as well as clinical trials will even strengthen this viewpoint and more RA patients will benefit from the application of such agents.
机译:尽管改变病情的抗风湿药(DMARD)已在临床中广泛使用,但到目前为止,类风湿关节炎(RA)尚不能完全治愈。因此,寻求用于治疗RA的新药物已成为风湿病学家和骨科医生的追求目标。由于RA的主要病理特征是炎症,因此抗炎药物的研究已成为热点。此外,最近发现了烟碱乙酰胆碱受体的抗炎和抗伤害感受功能以及相关机理。基于上述,有希望的是,烟碱型乙酰胆碱受体激动剂将用于RA的治疗。在体外,体内实验以及临床试验之后,这种观点甚至将得到加强,并且更多的RA患者将从此类药物的应用中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号